Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 18/20 | 0.55 |
| ▸ | CDK2 | P24941 | 18/20 | 0.55 |
| ▸ | CDK4 | P11802 | 10/20 | 0.55 |
| ▸ | CDK1 | P06493 | 8/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 16/20 | 0.52 |
| ▸ | CCND1 | P24385 | 9/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.52 |
| ▸ | CCND2 | P30279 | 1/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998733 | 0.84 | MYC (0.51) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL9096131 | 0.82 | CCNE1 (0.61) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL5216130 | 0.81 | MYC (0.44) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL1133564 | 0.79 | SMN1; SMN2 (0.42) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL5216840 | 0.79 | CCNE1 (0.67) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL16731888 | 0.76 | CCNE1 (0.68) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL8993668 | 0.76 | MYC (0.51) | CCNE1CDK2CDK4CDK1MYC | |
| SCHEMBL2690664 | 0.76 | FFAR2 (0.53) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL27479700 | 0.75 | CCNE1 (0.58) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL14394710 | 0.75 | MYC (0.44) | CCNE1CDK2CDK4CDK1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745377-B2 | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use | MERCK SHARP & DOHME CORP. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3068390-B1 | PIPERAZINE-IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160297792-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297792-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015073310-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015070367-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| EP-1042307-B1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2007-10-03 | — | — | EP | disclosed |
| CN-1160343-C | Aminothiazole inhibitors of cyclin dependent protein kinasses of cells | ����˹�ж�-����˹˹������˾ | 2004-08-04 | — | — | CN | disclosed |
| CN-1433408-A | Aminothiazole inhibitors of cyslin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6521759-B2 | Anticancer, antiarthritic, and antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-18 | — | — | US | disclosed |
| EP-1240153-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | Bristol-Myers Squibb Company (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6262096-B1 | IN COMBINATION WITH A MODULATOR OF P53 TRANSACTIVATION FORMULATED AS A FIXED DOSE. | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| WO-2001044217-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| CN-1278806-A | Aminothiazole inhibitors of cyclin dependent protein kinasses of cells | BRISTOL MYERS SQUIBB CO (US) | 2001-01-03 | — | — | CN | disclosed |
| EP-1042307-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6040321-A | ENZYME INHIBITOR TREATING CANCER, INFLAMMATION AND ARTHRITIS, NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, CARDIOVASCULAR DISEASES, VIRAL DISEASES AND FUNGAL DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999024416-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5491157-A | USING 2-AMINO-5-THIAZOLYL THIOCYANATE | EASTMAN KODAK COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| EP-0625307-A1 | Method and composition for the control of soilborne fungi and prevention of diseases caused by them | AMERICAN CYANAMID COMPANY (US) | 1994-11-23 | — | — | EP | disclosed |
| CN-1094890-A | The fungi that soil has and due to the method and composition of prevention, control and improvement of disease | AMERICAN AYANAMID COMPANY (US) | 1994-11-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745377-B2 | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use | CYP3A5, CYP3A43, CYP3A4 | CCNE1 3099/4885CDK2 1022/4885CDK4 889/4885 |
| US-20160297792-A1 | PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | CYP3A5, CYP3A43, CYP3A7 | CCNE1 3242/4885CDK2 1456/4885CDK4 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.